Parkinson's syndrome, also called tremor paralysis, occurs in adults who are middle-aged above, they are pathway degenerative diseases of substantia nigra and nigrostriatal. Parkinson's syndrome is a kind of chronic degenerative disorder of the central nervous system, it can damage patient's movement skills, language skills and other abilities. LRRK2 protein is a big protein which contains the activity of GTPase and kinase simultaneously. GTPase activity is regulated by GTPase-activating protein and GTP exchange factor.

       Laboratory in Medicine department of American Johns Hopkins University, first discovered the ArfGAP1 is the GTPase activating protein of LRRK2 in vivo and vitro to regulate LRRK2 toxicity. The results showed the GTPase function and importance of ArfGAP1 in LRRK2 toxicity studies and put forward new ideas for pathological study of LRRK2. GTPase regulation of LRRK2 can be used as target for drug design in Parkinson's disease. The research results " ArfGAP1 is the GTPase activating protein of LRRK2: mutual adjustment mechanism between ArfGAP1 and LRRK2 " successfully published in US core journal Neuroscience.

       In the experiment, loading control antibodies of beta-actin are from Tianjin Sungene biotech Co., Ltd. In Western-Blot test, band is uniform and reliable between groups and within group. The signal of loading control antibody is very strong, even if it diluted by ten thousand times, exposure time is only 1-5 seconds, it still give a very clear band, see figure below.